此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Modified Huanglian Wendan Decoction for Metabolic Syndrome

Effect of Modified Huanglian Wendan Decoction on Oxidative Stress in Patients With Metabolic Syndrome

This randomized controlled clinical study aims to evaluate the effect of Modified Huanglian Wendan Decoction on oxidative stress in patients with metabolic syndrome. A total of 180 patients with metabolic syndrome from The First Affiliated Hospital of Heilongjiang University of Chinese Medicine will be assigned to a control group or an observation group at a 1:1 ratio. Participants in both groups will receive lifestyle intervention and standard therapy, including antihypertensive, hypoglycemic, and lipid-lowering treatment. Participants in the observation group will additionally receive Modified Huanglian Wendan Decoction for 3 months. The study will compare changes in oxidative stress indicators, obesity-related parameters, blood pressure, glucose and lipid metabolism, and insulin resistance before and after treatment.

研究概览

详细说明

Metabolic syndrome is a cluster of metabolic abnormalities characterized by obesity, hypertension, dyslipidemia, impaired glucose metabolism, and insulin resistance. Oxidative stress is considered an important mechanism involved in the development and progression of metabolic syndrome. Traditional Chinese medicine may provide additional therapeutic benefits through multi-component and multi-target regulation.

This study is a single-center, randomized controlled clinical study conducted at The First Affiliated Hospital of Heilongjiang University of Chinese Medicine. A total of 180 eligible patients with metabolic syndrome will be enrolled and randomly assigned to a control group or an observation group in a 1:1 ratio. Randomization will be performed using a random number table or randomization software by an independent staff member who is not involved in participant recruitment, treatment, or statistical analysis.

All participants will receive lifestyle intervention, including health education, lifestyle modification, appropriate aerobic exercise, a low-salt and low-fat diet, reduced cholesterol intake, and increased dietary fiber intake. Participants in the control group will receive standard therapy, including valsartan capsules, metformin hydrochloride tablets, and atorvastatin calcium tablets. Participants in the observation group will receive Modified Huanglian Wendan Decoction in addition to the same lifestyle intervention and standard therapy used in the control group. The decoction will be administered orally twice daily for 3 months.

Outcome assessments will be performed at baseline and after 3 months of treatment. The primary outcomes are oxidative stress indicators, including malondialdehyde, superoxide dismutase, glutathione, glutathione peroxidase, catalase, and reactive oxygen species. Secondary outcomes include waist circumference, body mass index, waist-to-hip ratio, waist-to-height ratio, systolic blood pressure, diastolic blood pressure, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, fasting insulin, fasting plasma glucose, 2-hour postprandial glucose, glycated hemoglobin, homeostasis model assessment of insulin resistance, triglyceride-glucose index, and triglyceride to high-density lipoprotein cholesterol ratio.

The purpose of this study is to assess the clinical efficacy and safety of Modified Huanglian Wendan Decoction in patients with metabolic syndrome and to provide clinical evidence for traditional Chinese medicine in the management of metabolic syndrome and oxidative stress.

研究类型

介入性

注册 (实际的)

180

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Heilongjiang
      • Harbin、Heilongjiang、中国、150040
        • The First Affiliated Hospital of Heilongjiang University of Chinese Medicine

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Patients aged 18 to 75 years.
  • Male or female patients.
  • Patients diagnosed with metabolic syndrome according to applicable clinical diagnostic criteria.
  • Patients treated in the outpatient department or inpatient ward of The First Affiliated Hospital of Heilongjiang University of Chinese Medicine.
  • Patients who are able to understand the study procedures and cooperate with treatment, examinations, and follow-up.
  • Patients who voluntarily participate in the study and sign the written informed consent form.

Exclusion Criteria:

  • Patients with severe diseases of vital organs or systems, including severe cardiovascular, hepatic, renal, neurological, or hematopoietic diseases.
  • Patients with malignant tumors, autoimmune diseases, acute infectious diseases, or severe psychiatric disorders.
  • Pregnant or lactating women, or women planning pregnancy during the study period.
  • Patients with known allergy or intolerance to any study medication or herbal components used in this study.
  • Patients who have recently participated in another clinical study or are receiving other treatments that may affect the study outcomes.
  • Patients with poor compliance who cannot take the study medication regularly or complete follow-up.
  • Patients judged by the investigators to be unsuitable for participation in this study for any other reason.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Standard Therapy Group
Participants in this arm will receive lifestyle intervention and standard therapy for 3 months. Lifestyle intervention includes health education, lifestyle modification, appropriate aerobic exercise, a low-salt and low-fat diet, reduced cholesterol intake, and increased dietary fiber intake. Standard therapy includes valsartan capsules 80 mg orally once daily, metformin hydrochloride tablets 0.5 g orally three times daily, and atorvastatin calcium tablets 10 mg orally once daily.
Participants will receive lifestyle intervention, including basic health education, lifestyle modification, appropriate aerobic exercise for more than 30 minutes per day, a low-salt and low-fat diet, reduced cholesterol intake, and increased dietary fiber intake.
Standard therapy includes valsartan capsules 80 mg orally once daily, metformin hydrochloride tablets 0.5 g orally three times daily, and atorvastatin calcium tablets 10 mg orally once daily. Treatment will continue for 3 months.
实验性的:Modified Huanglian Wendan Decoction Group
Participants in this arm will receive Modified Huanglian Wendan Decoction in addition to the same lifestyle intervention and standard therapy used in the control group. Modified Huanglian Wendan Decoction will be prepared by the decoction room of The First Affiliated Hospital of Heilongjiang University of Chinese Medicine. The decoction will be administered orally at 150 mL twice daily, in the morning and evening, for 3 months.
Participants will receive lifestyle intervention, including basic health education, lifestyle modification, appropriate aerobic exercise for more than 30 minutes per day, a low-salt and low-fat diet, reduced cholesterol intake, and increased dietary fiber intake.
Standard therapy includes valsartan capsules 80 mg orally once daily, metformin hydrochloride tablets 0.5 g orally three times daily, and atorvastatin calcium tablets 10 mg orally once daily. Treatment will continue for 3 months.
Modified Huanglian Wendan Decoction consists of Coptidis Rhizoma 15 g, Pinelliae Rhizoma Praeparatum 10 g, Aurantii Fructus Immaturus 15 g, Bambusae Caulis in Taenias 10 g, Citri Reticulatae Pericarpium 15 g, Poria 15 g, Glycyrrhizae Radix et Rhizoma Praeparata cum Melle 10 g, Eucommiae Cortex 20 g, Achyranthis Bidentatae Radix 20 g, Puerariae Lobatae Radix 20 g, Salviae Miltiorrhizae Radix et Rhizoma 10 g, and Eupatorii Herba 15 g. The decoction will be prepared to 300 mL and administered orally at 150 mL twice daily, in the morning and evening, for 3 months.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change From Baseline in Malondialdehyde Level at 3 Months
大体时间:Baseline and 3 months after treatment
Serum malondialdehyde level will be measured using enzyme-linked immunosorbent assay.
Baseline and 3 months after treatment
Change From Baseline in Superoxide Dismutase Level at 3 Months
大体时间:Baseline and 3 months after treatment
Serum superoxide dismutase level will be measured using enzyme-linked immunosorbent assay.
Baseline and 3 months after treatment
Change From Baseline in Glutathione Level at 3 Months
大体时间:Baseline and 3 months after treatment
Serum glutathione level will be measured using enzyme-linked immunosorbent assay.
Baseline and 3 months after treatment
Change From Baseline in Glutathione Peroxidase Level at 3 Months
大体时间:Baseline and 3 months after treatment
Serum glutathione peroxidase level will be measured using enzyme-linked immunosorbent assay.
Baseline and 3 months after treatment
Change From Baseline in Catalase Level at 3 Months
大体时间:Baseline and 3 months after treatment
Serum catalase level will be measured using enzyme-linked immunosorbent assay.
Baseline and 3 months after treatment
Change From Baseline in Reactive Oxygen Species Level at 3 Months
大体时间:Baseline and 3 months after treatment
Serum reactive oxygen species level will be measured using enzyme-linked immunosorbent assay.
Baseline and 3 months after treatment

次要结果测量

结果测量
措施说明
大体时间
Change From Baseline in Waist Circumference at 3 Months
大体时间:Baseline and 3 months after treatment
Waist circumference will be measured in the fasting state in the morning at the minimum circumference between the lowest rib margin and the iliac crest.
Baseline and 3 months after treatment
Change From Baseline in Body Mass Index at 3 Months
大体时间:Baseline and 3 months after treatment
Body mass index will be calculated as body weight in kilograms divided by height squared in meters.
Baseline and 3 months after treatment
Change From Baseline in Waist-to-Hip Ratio at 3 Months
大体时间:Baseline and 3 months after treatment
Waist circumference and hip circumference will be measured, and waist-to-hip ratio will be calculated as waist circumference divided by hip circumference.
Baseline and 3 months after treatment
Change From Baseline in Waist-to-Height Ratio at 3 Months
大体时间:Baseline and 3 months after treatment
Waist circumference and height will be measured, and waist-to-height ratio will be calculated as waist circumference divided by height.
Baseline and 3 months after treatment
Change From Baseline in Systolic Blood Pressure at 3 Months
大体时间:Baseline and 3 months after treatment
Systolic blood pressure of the right upper arm will be measured before medication in the morning after at least 5 minutes of rest. The average value of three measurements will be recorded.
Baseline and 3 months after treatment
Change From Baseline in Diastolic Blood Pressure at 3 Months
大体时间:Baseline and 3 months after treatment
Diastolic blood pressure of the right upper arm will be measured before medication in the morning after at least 5 minutes of rest. The average value of three measurements will be recorded.
Baseline and 3 months after treatment
Change From Baseline in Total Cholesterol Level at 3 Months
大体时间:Baseline and 3 months after treatment
Total cholesterol level will be measured by enzymatic method using a biochemical analyzer.
Baseline and 3 months after treatment
Change From Baseline in Triglyceride Level at 3 Months
大体时间:Baseline and 3 months after treatment
Triglyceride level will be measured by enzymatic method using a biochemical analyzer.
Baseline and 3 months after treatment
Change From Baseline in High-Density Lipoprotein Cholesterol Level at 3 Months
大体时间:Baseline and 3 months after treatment
High-density lipoprotein cholesterol level will be measured using the ultracentrifugation method.
Baseline and 3 months after treatment
Change From Baseline in Low-Density Lipoprotein Cholesterol Level at 3 Months
大体时间:Baseline and 3 months after treatment
Low-density lipoprotein cholesterol level will be measured using the ultracentrifugation method.
Baseline and 3 months after treatment
Change From Baseline in Fasting Insulin Level at 3 Months
大体时间:Baseline and 3 months after treatment
Fasting insulin level will be measured using radioimmunoassay.
Baseline and 3 months after treatment
Change From Baseline in Fasting Plasma Glucose Level at 3 Months
大体时间:Baseline and 3 months after treatment
Fasting plasma glucose level will be measured by enzymatic method using a biochemical analyzer.
Baseline and 3 months after treatment
Change From Baseline in 2-Hour Postprandial Glucose Level at 3 Months
大体时间:Baseline and 3 months after treatment
Two-hour postprandial glucose level will be measured by enzymatic method using a biochemical analyzer.
Baseline and 3 months after treatment
Change From Baseline in Glycated Hemoglobin Level at 3 Months
大体时间:Baseline and 3 months after treatment
Glycated hemoglobin level will be measured using latex immunoagglutination assay.
Baseline and 3 months after treatment
Change From Baseline in Homeostasis Model Assessment of Insulin Resistance at 3 Months
大体时间:Baseline and 3 months after treatment
Homeostasis model assessment of insulin resistance will be calculated using the formula: fasting insulin multiplied by fasting plasma glucose divided by 22.5.
Baseline and 3 months after treatment
Change From Baseline in Triglyceride-Glucose Index at 3 Months
大体时间:Baseline and 3 months after treatment
The triglyceride-glucose index will be calculated using the formula: natural logarithm of triglycerides multiplied by plasma glucose divided by 2.
Baseline and 3 months after treatment
Change From Baseline in Triglyceride to High-Density Lipoprotein Cholesterol Ratio at 3 Months
大体时间:Baseline and 3 months after treatment
The triglyceride to high-density lipoprotein cholesterol ratio will be calculated based on triglyceride and high-density lipoprotein cholesterol levels.
Baseline and 3 months after treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年10月1日

初级完成 (实际的)

2025年8月31日

研究完成 (实际的)

2025年8月31日

研究注册日期

首次提交

2026年7月9日

首先提交符合 QC 标准的

2026年7月9日

首次发布 (实际的)

2026年7月14日

研究记录更新

最后更新发布 (实际的)

2026年7月14日

上次提交的符合 QC 标准的更新

2026年7月9日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be shared publicly because the study data contain personal health information, laboratory test results, treatment information, and oxidative stress-related outcomes from patients with metabolic syndrome. All study data will be de-identified and managed by the research team in accordance with the approved protocol, informed consent, ethical approval, and institutional data protection requirements.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅